Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy weight-loss drug four years ago,

The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, particularly in the U.S.

First-quarter sales rise 18 per cent but Danish pharma group blames custom preparations at pharmacies for weaker take-up